Generics Bulletin Explains: The Next Wave Of US Humira Biosimilars

Start Of July Will See An Explosion Of Competition On Adalimumab In US From Eight Rivals

 
• By Dave Wallace

Following Amgen’s debut of the first US Humira rival earlier this year, as many as eight further FDA-approved adalimumab biosimilars are about to launch. Generics Bulletin breaks down all the different players and how they are positioning themselves in such a competitive market.

Black running track with white markings for positions 1 to 8
Eight further FDA-approved Humira biosimilars are set to launch • Source: Shutterstock

Anyone with even a passing interest in the global off-patent industry will likely be aware of the significance of 2023 for the US biosimilars market.

FDA-approved adalimumab biosimilars

Amgen’s Amjevita (adalimumab-atto)

Biocon’s Hulio (adalimumab-fkjp)

Boehringer Ingelheim’s Cyltezo (adalimumab-adbm)

Celltrion’s Yuflyma (adalimumab-aaty)

Coherus’s Yusimry (adalimumab-aqvh)

Fresenius Kabi’s Idacio (adalimumab-aacf)

Humira – for a long time the world’s top-selling drug, and still one of the biggest brands in the business – finally faced US biosimilar competition this year, with Amgen at the end of January launching the first of many

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Generics Bulletin for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Biosimilars

More from Products